MAA
EVFM

Managed Account Advisors’s Evofem Biosciences, Inc. Common Stock EVFM Stock Holding History

Managed Account Advisors’s Portfolio EVFM Stock Details EVFM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-9
Closed -$7K – 3153
2015
Q1 		$7K Buy
+9
New +$5.75K ﹤0.01% 2856

Other funds holding EVFM

CV
Clarus Ventures Cambridge, Massachusetts $425M AUM 26.13% 1-Year Est. Return
CPCM
Clifton Park Capital Management Wilmington, Delaware $881M AUM 5.59% 1-Year Est. Return
CA
Cortland Advisers Wilmington, Delaware $2.18B AUM 8.82% 1-Year Est. Return
AC
Amici Capital New York $257M AUM 4.88% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PSC
Piper Sandler & Co Minneapolis, Minnesota $135M AUM 0.15% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Managed Account Advisors's EVFM Position: Q2 2015 in Review

Managed Account Advisors sold out of Evofem Biosciences, Inc. Common Stock (EVFM) in Q2 2015, closing a stake of 9 shares — an estimated $7K sold.

Managed Account Advisors first reported a position in EVFM in Q1 2015 and held it in 1 quarter. The position peaked at $7K in Q1 2015. 25 funds tracked by Wall St. Rank hold EVFM as of Q2 2015.

  • Managed Account Advisors reported no remaining Evofem Biosciences, Inc. Common Stock position as of Q2 2015 after selling out during the quarter.
  • Managed Account Advisors sold 9 Evofem Biosciences, Inc. Common Stock shares in Q2 2015, an estimated $7K.
  • Managed Account Advisors first reported a position in Evofem Biosciences, Inc. Common Stock in Q1 2015 and held it in 1 quarter.
  • Managed Account Advisors's Evofem Biosciences, Inc. Common Stock position peaked at $7K in Q1 2015.
  • 25 funds tracked by Wall St. Rank held Evofem Biosciences, Inc. Common Stock as of Q2 2015.

Based on Managed Account Advisors's 13F filing for Q2 2015, filed 14 Aug 2015.